Key result
This article reviews the rationale, pharmacokinetics, and pharmacodynamics of the neutral endopeptidase inhibitor candoxatril in healthy individuals and patients with chronic heart failure.
Why the study?
Does candoxatril have therapeutic potential compared to furosemide and captopril in the treatment of chronic cardiac failure?
Does candoxatril have therapeutic potential compared to furosemide and captopril in the treatment of chronic cardiac failure?
This review outlines the rationale, pharmacokinetics, and pharmacodynamics of the neutral endopeptidase inhibitor candoxatril for the treatment of chronic heart failure.
Answers are grounded in this paper and cite their sources.
Review of candoxatril PK/PD in HF does not guide practice; leaves open efficacy versus furosemide or captopril.
Candoxatril (UK-79300) is the orally-active prodrug of candoxatrilat (UK-73967), the active enantiomer of (+/-)candoxatrilat (UK-69578), a potent neutral endopeptidase (NEP) inhibitor. This article describes the rationale behind the use of such a drug in the treatment of chronic heart failure in man. It further describes the pharmacokinetics and pharmacodynamics of candoxatril in normal healthy individuals and in patients with chronic cardiac failure. In addition, we describe the initial results comparing candoxatril with furosemide and captopril in human heart failure.
No takes yet. Share an insight, caveat, or question.
McDowell et al. (1999) conducted a review in chronic cardiac failure. Candoxatril vs. furosemide and captopril was evaluated. This article reviews the rationale, pharmacokinetics, and pharmacodynamics of the neutral endopeptidase inhibitor candoxatril in healthy individuals and patients with chronic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: